医学
脂质体
药物输送
黑质
帕金森病
血脑屏障
药物输送到大脑
药品
疾病
药理学
帕金森病
多巴胺
靶向给药
神经科学
化学
中枢神经系统
内科学
心理学
有机化学
生物化学
作者
Bhumika Kumar,Mukesh K. Pandey,Faheem Hyder Pottoo,Faizana Fayaz,Anil Kumar Sharma,Prabhat Kumar Sahoo
标识
DOI:10.2174/1381612826666200128145124
摘要
Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI